The current prescription patterns for essential hypertension and the efficacy, safety, tolerability and costeffectiveness of the newer antihypertensive drugs were evaluated in Nigerian patients. The findings were compared with that of a previous study conducted in the same tertiary hospital 10 years earlier. A crosssectional evaluation of blood pressure (BP) control in a hypertension clinic was undertaken among 150 Nigerian patients aged 61712 years (55% females), with a duration of treatment on a particular drug class or combination of 973 months. The initial blood pressure was 176720/108711 mmHg and 22% of the patient had concurrent diabetes mellitus. Thiazide diuretics (D) alone or in combination remained the most commonly prescribed drugs in 56% of all patients. There were significant increases in the prescriptions of calcium channel blockers (CCBs) (51%), Po0.0001, and ACEinhibitors (ACEIs) (24%), Po0.0001, but a slight reduction in the use of methyldopa, and fixed drug combinations (Po0.01) compared to the previous study. The fall in systolic blood pressure on D (r ¼ 0.65, Po0.001) or CCB (r ¼ 0.48, Po0.02) was significantly correlated with the initial systolic blood pressure, but not age. More patients achieved normotension BPo140/90 mmHg on CCB monotherapy (71%), than D monotherapy (56%). Combination therapy with ACEIs+D or methyldopa+thia-zides normalized BP in 63 and 68%, respectively. Pulse pressure, a surrogate marker for cardiovascular complications and mortality in essential hypertension, was significantly reduced (Po0.01) equally by all treatments, with 95% confidence intervals ranging from À28 to À1 mmHg. However, hypertensive-diabetic (HT-DM) patients (n ¼ 33) exhibited no significant change in pulse pressure in response to treatment. Adverse drug reactions that occurred in 11% were impotence or postural dizziness with D, headache and pitting oedema with CCB, and dry cough with ACEI. Pharmaco-economic comparison of the drug classes revealed that for every US dollar ($) spent per month, the percentage of treated patients attaining normotension was 18.6 for D, 4.73 for CCB, 3.5 for ACEI+D and 13.6 for methyldopa+thiazides. A combination of ACEI+CCB or D was the preferred treatment for hypertensive-diabetic Nigerians, but only 24% attained a BPo130/85 mmHg. These results demonstrate a shift in trend to a more rational and efficacious treatment of hypertension over a 10 year period. This may be associated, at least in part, with the intensive and continuous education of the prescribers in rational drug use and the introduction of a hospital formulary. Methyldopa is still a highly efficacious and costeffective drug in this population. Black HT-DM Africans still constitute a subgroup who not only require more and costlier antihypertensive drugs, but whose BP control is suboptimal, and exhibit a poor therapeutic response to other risk factors (pulse pressure) that constitute a continuing risk for cardiovascular mortality.
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Introduction
Essential hypertension remains the most common cardiovascular disease of black Africans 1,2 and a leading public health risk factor on a global scale. In black Africans, hypertension has a higher ageadjusted prevalence 3 and the ravage of hypertension is particularly severe. It is the leading cause of congestive heart failure, 4,5 chronic renal failure, 5, 6 cerebrovascular disease 7, 8 of hospitalization, and of cardiovascular mortality and sudden cardiac death. [9] [10] [11] The need for early, effective and rational treatment becomes imperative in the light of the dismal prognosis of hypertension in black Africans.
More than 10 years ago, we reported on the pattern of prescription of drugs for the treatment of hypertension in Nigerians, as well as the tolerability of the antihypertensive drugs, their efficacy and cost-effectiveness. 12 Since our therapeutic audit in 1989, 12 novel antihypertensive drugs such as calcium antagonists 13, 14 and angiotensin-converting enzyme inhibitors (ACEIs) 14, 15 have been introduced into routine clinical practice in Nigeria. In our earlier study, 12 we highlighted the much more dismal prognosis of patients with concurrent hypertension with diabetes, which has been confirmed in a more recent study. 16 Furthermore, novel parameters in the arterial pulse contour, which have recently been shown to possess important prognostic value, were not evaluated in our earlier study. For example, the pulse pressure has been reported to be a strong predictor of not only congestive heart failure, strokes and myocardial infarction but also of total cardiovascular mortality. [17] [18] [19] [20] Since our last therapeutic audit of hypertension treatment in Nigerians, 12 we have developed a hypertension clinic, in which individualized therapy and continuous education in clinical pharmacology are emphasized. A hospital drug formulary was also introduced. The optimal management of hypertension involves balancing among its risks, costs and risks of treatment, and the trade-offs between the risks and benefits and the cost and quality of therapy. 21 The purposes of our present study are (a) to evaluate any shift in trends in the prescription patterns in the treatment of hypertension in the same tertiary referral centre, where the earlier audit was conducted, (b) to assess the rationality of prescriptions and the cost-effectiveness based on individualized therapeutic goals, especially in high-risk patients with comorbidity, and (c) to assess the impact therapy on prognostic surrogate end points, including pulse pressure. Our findings demonstrate a substantial shift toward a more rational use of antihypertensive drugs in Nigerians, while highlighting areas of residual problems requiring attention.
Materials and methods
We conducted a cross-sectional study of 150 consecutive new patients who were currently receiving treatment for essential hypertension with or without diabetes mellitus in the hypertension and cardiology clinics of the Obafemi Awolowo University Teaching hospital complex, Ile-Ife, a tertiary referral centre in Western Nigeria. This was the same hospital from which we conducted our earlier therapeutic audit, as reported by Oyewo et al 12 in 1989. The hospital ethical review committee reviewed and approved the study, to which the subjects gave informed witnessed consent. The patients' medical history, demographic data, clinical parameters at diagnosis, comorbidity, types of antihypertensive medications and dosage level, duration of treatment, compliance and adverse effects were extracted into a standardized questionnaire from their case files. Criteria for inclusion in the study were recently admitted clinic patients, Nigerians, who had received antihypertensive drug therapy for at least 6 months. Patients with hypertensive chronic renal failure or congestive heart failure were excluded from the compilation. The reported results represent the totality of patients managed at this clinic, who met the inclusion criteria and did not have the exclusion criteria. Thereafter, the patient underwent a physical examination and the blood pressure (BP) was measured twice in the sitting position after 10 min of rest. The average of the BPs was taken as the post-treatment pressure, and the pulse pressure (PP) is the difference between systolic (SBP) and diastolic blood pressures (DBP). BP control (efficacy) was ranked on a categorical scale of 5, which denotes attainment of normotension (BPo140/90 mmHg) sitting, to a score of 1 (no change from initial BP or higher) as we have previously reported. 12 Adverse effects were elicited by direct questioning and from the case record.
Statistical analyses
Data are mean 7 s.d. Descriptive statistics, with 95% confidence intervals, have been quoted. Evaluation of a shift in the prescription trend for a drug was undertaken using the w 2 test for proportionate data. The comparison of drug efficacy by drug class was undertaken using one-way analysis of variance (ANOVA). The impact of drug class or combinations on the pulse pressure (DPP mmHg) was evaluated by a one-sample t-test, with a two-tailed P-value, and 95% confidence intervals for a difference quoted. The relation between age or initial systolic blood pressure, and the fall in systolic pressure (ÀDSBP mmHg) were assessed by linear regression analysis. The 95% confidence intervals for the slope and intercept were quoted. The null hypothesis was of no difference rejected at Po0.05.
Results

Patient demographic data, comorbidity and risk profile
The patients were aged 61 7 12 years, with a range of 40-90 years. The population was 54% female (81/150). The BP was 176 7 20/108 7 11 mmHg and the sitting heart rate was 83 7 17 bpm. The duration of hypertension was 6 7 5 years and left ventricular hypertrophy, determined by 12 lead ECG or 2-D echocardiography, was detected in 37 patients or 25% at presentation. In all, 33 patients (22%) had concurrent diabetes mellitus (Table 1) . Severe hypertension (SBP4200 mmHg) was present in 17.3% (26/150), the highest pressure recorded at presentation being 240/150 mmHg. Seven cases (4.6%) had suffered a cerebrovascular episode (stroke) as a consequence of the hypertension. The serum creatinine at presentation was 114 7 36 mmol/ l. There was no report of ischaemic heart disease or prior myocardial infarction. The pulse pressure averaged 68 mmHg.
Other comorbid conditions
Apart from the comorbidity of diabetes mellitus (mostly non-insulin dependent diabetes mellitusF21%), four patients (2.67%) had concurrent bronchial asthma, another two (1.33%) had peptic ulcer with essential hypertension, yet another two patients had psychotic depression (1.33%), and one (0.67%) had a history of tonic clonic seizures. All these patients were on appropriate therapy for their comorbid medical diseases.
Antihypertensive drug prescriptions pattern
The duration of treatment with antihypertensive drugs among the 150 patients in the clinic ranged from 6 months to 20 months, the mean being 9 7 3 months. In all, 30 hypertensive patients (20%) had been receiving the same drug for at least 1 year. A total of 58 patients (39%) received one drug (monotherapy, and 79 (52%) received two, while 13 patients (8.7%) received three antihypertensive drugs. Thiazide diuretics (D) were the most frequently prescribed antihypertensive agent, accounting for 56% of all prescriptions, either as monotherapy or in combination. The thiazide drugs employed were fixed drug combination of amiloride and hydrochlorothiazide 1 tablet/day, hydrochlorothiazide 25-50 mg/day or bendrofluazide 5 mg daily. Calcium channel blockers (CCBs), amlodipine 2.5-10 mg/day, lacidipine 4-8 mg/day or nifedipine retard 20 mg twice daily were used in 51% of the cases. ACEIs (enalapril 5-10 mg, captopril 25 mg twice daily or lisinopril 10 mg daily) were used in 24% of patients always in combination with a diuretic or CCB. A fixed drug combination of 20 mg lisinopril and 12.5 mg hydrochlorothiazide was also employed. The centrally acting sympathoplegic drug methyldopa (500-1, 500 mg/day) was employed in combination in 28% of the patients, while the use of an a-1 adrenergic antagonist (prazosin 1-5 mg/day) or a b-adrenergic blocker (atenolol 50-100 mg daily or propranolol 160-240 mg daily) accounted for 10 and 5%, respectively. In all, 11 patients (7%) were receiving fixed dose combination with regroton (reserpine+thiazide) or brinerdine (clopamide, dyazide, and dihydro-ergocristine) one tablet daily. There was no significant change in the proportion of patients on diuretics in 1989, compared to the present study in 2000 (w 2 ¼ 1.87, df 1, P ¼ 0.17). There were, however, significant increases in the proportion of patients prescribed angiotensin-converting inhibitors (Po0.00001) or CCBs (Po0.00001), but a moderate decrease in the prescription of methyldopa (Po0.0001) in the year 2000 compared to 1989. A comparison of the prescription pattern in 1989 12 with the present study, indicating a shifting trend, is shown in Table 2 .
Antihypertensive drug efficacy: determinants and class comparison
There were significant falls in SBP of À32 7 26 mm Hg (Po0.0001) and DBP fall of À21 7 6 mmHg (Po0.0001) with drug treatment. There was no statistically significant change in heart rate from 88 7 10 to 86 7 8 bpm. A total of 47% (70 patients) had achieved normotension (BPo140/90 mmHg) at the time of evaluation in the clinic; 38 patients (25.3%) attained a blood pressure o130/85 mmHg. More patients on CCB monotherapy (71%) achieved normotension than any other group; this was followed by the diuretic group monotherapy, with a normotension rate of 56%. The ACEI+D combination resulted in normotension in 63%, while methyldopa+D resulted in normal blood pressure in 68% of those treated. These results are summarized in Table 3 . The determinants of the antihypertensive response to diuretic or CCB monotherapy were evaluated. Both for D (P ¼ 0.0006) and CCB (P ¼ 0.02), the initial systolic BP, but not the patient's age, was shown to be a good predictor of the fall in SBP (see Figure 1a-d) . In addition, both CCB (DPP ¼ À12.8 mmHg) or D monotherapy (À18 mmHg), and the combinations ACEI+D (À10.8 mmHg) or methyldopa+D (À18.1 mmHg) (36) significantly reduced the pulse pressure, a novel cardiovascular risk for morbidity and mortality (see Figures 2 and 3 ).
Rationality of therapy: assessment of treatment and efficacy in different risk groups
Hypertensive-diabetic patients A total of 33 patients (19 females, 57%) had concurrent hypertension with diabetes mellitus. One of the patients had a history of thrombotic stroke. In all, 51% (17 patients) attained normotension with BPo140/90 mmHg; 24% (eight patients) attained the JNC-VI/ISH/WHO target blood pressure of o130/o85 mmHg. The drugs employed in the therapy of the patients were CCBs alone or in combination (25/33, or 76%), ACEI+D combination (zestoretic) in five cases (15%), ACEI+CCBsF12 patients (36%) and methyldopa with diureticFfour patients (12%). Low-dose aspirin 80-160 mg daily was used mostly in male patients. These medications, although they lowered SBP and DBP significantly in the patients, had no significant impact on the pulse pressure (DPP ¼ À5.6 mmHg), in contrast to nondiabetic hypertensives (see Figures 2 and 3) . One patient received a cardioselective b-blocker, atenolol. No diabetic patient was treated with diuretics only, but many received an ACEI with a D or calcium antagonist.
Other comorbid states and therapeutic choices
The four patients with bronchial asthma with hypertension were treated with CCBs (two patients) or moduretic thiazide (one patient), or moduretic+ methyldopa+ACEI (one patient). Two patients with peptic ulcer disease both received moduretic, a K+ sparing diuretic. A patient with osteoarthritis, which required prolonged use of nonsteroidal antiinflammatory drugs (NSAIDS), had his hypertension controlled on amlodipine. Another patient with concurrent tonic clonic epilepsy was treated with a CCB, while another patient with depression was prescribed low-dose b-blocker, atenolol.
Adverse effects and tolerability
The majority of patients had a good tolerance to the antihypertensive drugs prescribed. In all, 16 patients (11%) experienced a significant adverse reaction. There was an equal sex distribution in the incidence of the reactions. The age range of affected was from 40 to 90 years, being 40-90 years for males and 52-78 years for females. D (19%) or CCBs ( 8%) were the most commonly associated with adverse reactions alone or in combination, and were responsible for 62% of total adverse reaction burden. D caused impotence and sexual dysfunction in men, and postural dizziness in both sexes. CCBs *Statistically significant change in frequency of prescriptions between the present study and the earlier study published in 1989. 12 **Po0.01; *** Po0.001; ****Po0.0001. a The present study excluded hypertensive chronic renal failure or congestive heart failure patients who required the use of b-adrenoceptor blockers. Score of 5=normotension, Score of 4XÀ20/À10 mmHg, Score 3=À10-19/À5-9 mmHg, Score 2=À1-9 À1-4 mmHg, Score 1=no BP change or higher.
Prescription trends and efficacy of newer antihypertensive drugs in Nigerians AQ Adigun et al were associated with pedal swelling and headaches, while ACEIs caused a persistent dry cough in 4/30 users, or 11.1%, three of whom were women. Six of the 16 patients (37.5%) who experienced an adverse effect had a comorbid condition (two had diabetes mellitus, one each had osteoarthritis, bronchial asthma, onchocerciasis or pulmonary tuberculosis).
Discussion
In this comparison of the current therapeutics of hypertension in Nigerians with the situation 10 years prior, the most striking change is the significant increase in the prescription frequency of CCBs and ACEIs. CCBs have been shown in individual controlled clinical trials to be a safe and effective monotherapy of moderate to severe hypertension in Nigerians, 13, 14, 22 and international and US studies, in general, indicate that CCBs are perhaps the single most efficacious antihypertensive drug class in black Africans. [23] [24] [25] In all, 71% of all the patients attained normotension with CCBs, a figure not substantially different from reports in AfricanAmericans. 23 Recent large multicentre studies (such as INSIGHT 25 and NORDIL 24 ), which compared calcium antagonists with b-blockers and D, showed that the calcium antagonist nifedipne 25 was equally effective in reducing cardiovascular complications and death to a similar extent to the established older agents. 25 The NORDIL study established that diltiazem reduced blood pressure, cerebrovascular diseases and death to a similar extent to D. 24 Based on these reports, it seems tenable to extrapolate that there is at least a therapeutic equivalence of D with CCBs in preventing target organ complications in hypertension. The proportion of our patients receiving D only decreased insignificantly. D were, however, the drugs with not only the second highest BP normalization rate (after CCBs), but were commonly used as firstline drugs and in combination with all other drug classes. Thus, the biochemical heterogeneity of essential hypertension, with black African having low renin-hypertension, probably underlies the efficacy of thiazides and CCBs in Nigerians. In a randomized single blind comparison of hydrochlorothiazide and amlodipine, no significant differences in antihypertensive effects were found, 14 but the diuretics caused hypokalaemia.
14 Thus, the choice of first-line antihypertensive drugs lies between CCBs and diuretics in Nigerians.
Both CCB and thiazide antihypertensive efficacy correlated with the initial SBP. However, the costeffectiveness analysis (expressed as a percentage of treated patients achieving normal BP, per monthly drug expenditure in US dollars $) indicates that at the same monthly expenditure, D will normalize blood pressures in five-fold more patients, compared to CCBs. This is of especial relevance at the population level, where drug cost affects compliance and hence BP control and target organ damage load. In turn, the complication rates affect the total health expenditure. With the annual low per capita income of Nigerians, of less than $300, 26 a vast majority of hypertensive patients can hardly afford the newer and more expensive drugs, at the recommended doses. However, at the individual level, comorbidity, affordability and adverse reaction profile must be collective factors in the therapeutic choices. We therefore propose a paradigm of drug choice as follows: antihypertensive drug choice ¼ drug cost-effectiveness in the patients' comorbid state or target organ complication profileÀadverse drug reaction frequency and/or severity. Thus, despite cost or expenditure, even more expensive drugs such as ACEIs must be included in the therapeutic regime of hypertensive patients with left ventricular hypertrophy (owing to the regression of the ventricular enlargement), but this choice will also be influenced in the long term by the presence or severity of ACEI-induced cough or angioedema in the particular patient, since the frequencies of these adverse effects are high at 27 and 0.54%, respectively, in Nigerians. 27 Another important therapeutic finding is the continued utility and efficacy of the methyldopa-D combination, especially in moderate to severe hypertension. There are reports of ethnic differences in the pharmacokinetics of dihydropyridine CCB nifedipine, which is claimed to exhibit slower clearance in southeast Asians as well as in Nigerians. 28 We, however, fail to identify any significant difference in nifedipine dose requirement in our patient population, in comparison to the recommended doses. The use of ACEI for hypertension also showed a marked and significant increase, especially in combination with D or CCBs. Although ACEI monotherapy of essential hypertension in Nigerians 13 and other blacks patients is of poor antihypertensive efficacy, ACEI+D has been shown to control BP and reverse proteinuria in hypertensive-diabetics 29 as well as in patients with chronic renal disease. 30 ACEIs have also reduced hospital mortality in Nigerians with hypertensive heart failure. 31 In the present study, concurrent hypertension with diabetes (HT-DM) was present in 22% of all the patients, a value higher than the earlier study result of 12%. 12 The preferred treatment for HT-DM in the present study was CCBs with ACEI or ACEI with D. The appropriate choice of drug treatment in this critical comorbid state is evidence of improved rationality of drug prescription in general. In all, 51% of HT-DM patients attained normotension, but only 24% achieved the WHO/ISH recommended BP level of o130/o85 mmHg. 32 The treatment of this high-risk group of patients needs to be particularly aggressive, given their dismal prognosis, which we have reported about earlier. 12, 16 Another finding of interest is the effect of various drug classes on the brachial arterial pulse pressure, which is now a recognized independent risk factor for cardiovascular mortality. [17] [18] [19] [20] 33 Both D and CCB monotherapy significantly reduced (Po0.001) the pulse pressure (Figure 2 ). Combination therapy of D with ACEI or methyldopa also reduced the pulse pressure, in addition to the significant antihypertensive action. The fall in pulse pressure on D may contribute to the reduction in stroke frequency and morbidity, which has been reported in large-scale clinical trials of essential hypertension. 19, 34 However, HT-DM patients had no significant reduction in pulse pressure, despite falls in SBP and DBP. The fall in pulse pressure in HT-DM patients was À5.6 mmHg, with a 95% confidence interval of À15.8 to 4.7 mmHg. This was not influenced by the antihypertensive treatment, as neither ACEI+D, nor CCB alone, or ACEI+CCB significantly reduced pulse pressure in HT-DM (see Figure 3) . Age-and sex-matched nondiabetic hypertensives showed a significant reduction in pulse pressure (À18.3 mmHg, 95% confidence interval, À1.5 to À23.3 mmHg), which was significantly greater than in the HT-DM cohort (P ¼ 0.0012) (Figure 3) . The attenuation of pulse pressure fall in HT-DM patients is concordant with earlier reports 33 and findings from the INSIGHT study, 35 and may reflect the more severe endothelial damage in diabetes, as disclosed by C-reactive protein levels 36 affecting the response to the systolic upstroke of the arterial wave. [17] [18] [19] [20] This finding reinforces the need to specifically target reduction in pulse pressure as a therapeutic goal in HT-DM patients. In the INSIGHT study, 35 diabetic patients with hypertension were resistant to treatment and required a second or third antihypertensive drug, 40 and 100% more frequently, respectively, than nondiabetic hypertensives. Thus, in addition to the enhanced risk, the HT-DM patients carry a greater economic burden in the control of their BP.
b-Adrenoceptor blockers were not commonly used in this cohort of essential hypertension (5%), because of the established poor response to the agents in black Africans. The b-blockers are, however, frequently employed in chronic renal failure and chronic congestive heart failure associated with hypertension in our practice.
Our study reflects the changes in one tertiary health-care centre in Nigeria. In comparison to the earlier therapeutic audit, 12 there is increased and cost-effective use of newer antihypertensive agents. The older agents, with proven clinical trial efficacy Percentage of adverse drug reaction calculated as frequency of reactions in the patient population in each drug class as stated in Table 3 .
Prescription trends and efficacy of newer antihypertensive drugs in Nigerians AQ Adigun et al of prophylaxis against strokes and heart failure, are also still commonly used. Methyldopa, in particular, is still a useful adjunctive therapy in severe hypertension, and can reduce pulse pressure greatly. Aspirin use was found mainly in male HT-DM patients, but only 24% of patients attain the WHO/ ISH standard of control. 32 ACEIs in combination with a diuretic or calcium antagonist exhibit renoprotective and cardioprotective properties in large multicentre studies. This combination is also the preferred treatment in (HT-DM) Nigerians, because it has been shown to lower blood pressure, significantly decrease 24 h proteinuria and raise plasma albumin concentrations in Nigerian patients, with the comorbidity. 29, 30 The improvement in the overall care and control of hypertension in our centre is probably the culmination of several factors. These include a separate hypertension clinic and management by a team guided by an agreed treatment protocol, through the development of a hospital drug formulary, drug compliance reinforcement by family intervention, as well as continuous education of the prescribers in the clinical pharmacology of antihypertensive drugs. This model may be a useful approach to the control of hypertension in socioeconomic circumstances, similar to ours.
